Liver cancer trial aims to shrink tumors before surgery with immune booster
NCT ID NCT07268131
First seen Jun 26, 2026 · Last updated Jul 31, 2026 · Updated 4 times
Summary
This phase II trial tests whether combining a liver-directed procedure (TACE) with an immunotherapy drug (QL1706) before surgery, followed by more immunotherapy after surgery, can help patients with liver cancer that is too large or numerous for standard transplant criteria. The study will enroll 30 adults with resectable BCLC stage A or B hepatocellular carcinoma. The main goal is to see if at least 90% of the tumor is killed or shrunk by the time of surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- QL1706 (a combination of two immune-boosting drugs, iparomlimab and tuvonralimab) plus transarterial chemoembolization (TACE)
- What this could lead to
- If successful, this approach could improve the chance of eliminating liver tumors before surgery and reduce the risk of cancer returning afterward.
- What could go wrong
- This is a small, early-phase trial with only 30 participants, so results may not apply to everyone. The combination of TACE and immunotherapy can cause serious side effects, and it is not yet known if it will improve long-term outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
HuaShan Hospital, Fudan University
RECRUITINGShanghai, Shanghai Municipality, 200040, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a 'No-Touch' microwave technique match surgery for liver tumors?
- Can blood tests reveal how liver and bile duct cancers respond to treatment?
- AI-Powered surveillance may outsmart liver cancer recurrence
- Blood markers may forecast liver cancer treatment success
- Can a diabetes drug help fight liver cancer? a trial puts it to the test
- Can a triple therapy shrink untreatable liver tumors?